Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
88
datasets available to search
ShareScore release 0.7.1
Dataset results
88 results for “guselkumab”
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
ClinicalTrials.gov study NCT03553823. IPD Sharing: UNDECIDED. Countries: 3. Publications: 1.
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
ClinicalTrials.gov study NCT03573323. IPD Sharing: YES. Countries: 3. Publications: 4.
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
ClinicalTrials.gov study NCT02207231. IPD Sharing: Not stated. Countries: 10. Publications: 10.
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ClinicalTrials.gov study NCT03451851. IPD Sharing: Not stated. Countries: 9. Publications: 2.
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
ClinicalTrials.gov study NCT02203032. IPD Sharing: Not stated. Countries: 10. Publications: 2.
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necros
ClinicalTrials.gov study NCT03162796. IPD Sharing: Not stated. Countries: 13. Publications: 15.
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.gov study NCT05528510. IPD Sharing: YES. Countries: 25. Publications: 1.
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
ClinicalTrials.gov study NCT02207244. IPD Sharing: Not stated. Countries: 9. Publications: 10.
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
ClinicalTrials.gov study NCT03818035. IPD Sharing: YES. Countries: 2. Publications: 2.
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
ClinicalTrials.gov study NCT02641730. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
ClinicalTrials.gov study NCT03090100. IPD Sharing: Not stated. Countries: 9. Publications: 4.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov study NCT03466411. IPD Sharing: Not stated. Countries: 43. Publications: 4.
Ultrasound and Proteomics for Guselkumab Response Assessment in Crohn's Disease (UPGRADE).
ClinicalTrials.gov study NCT07246460. IPD Sharing: NO. Countries: 1. Publications: 2.
Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
ClinicalTrials.gov study NCT03975153. IPD Sharing: NO. Countries: 1. Publications: 1.
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
ClinicalTrials.gov study NCT02905331. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
ClinicalTrials.gov study NCT04533737. IPD Sharing: NO. Countries: 12. Publications: 1.
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
ClinicalTrials.gov study NCT03628924. IPD Sharing: Not stated. Countries: 6. Publications: 1.
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
ClinicalTrials.gov study NCT03158285. IPD Sharing: Not stated. Countries: 13. Publications: 27.
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.gov study NCT05197049. IPD Sharing: YES. Countries: 27. Publications: 1.
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
ClinicalTrials.gov study NCT05272150. IPD Sharing: YES. Countries: 2. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.